ReVision Optics, Inc. Advances PresbyLens into Phase 3 Clinical Trial for Improving Near Vision in Patients with Presbyopia
6/11/2012 10:14:40 AM
LAKE FOREST, Calif.--(BUSINESS WIRE)--ReVision Optics®, Inc. (RVO), a leader in implantable inlay technology to treat presbyopia, announces the advancement of its proprietary product PresbyLens™ into the final phase of its U.S. clinical trial under an Investigational Device Exemption (IDE). PresbyLens is a clear, circular corneal inlay comprised of approximately 80% water and is less than half the thickness of a human hair.
comments powered by